Liriano Felix, Hatten Candace, Schwartz Thomas L
College of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Department of Psychiatry and Behavioral Sciences, Montefiore Medical Center, Bronx, NY 10467, USA.
Drugs Context. 2019 Apr 8;8:212305. doi: 10.7573/dic.212305. eCollection 2019.
Post-traumatic stress disorder (PTSD) continues to make headlines given multiple military engagements across the world and civilian traumas, and resultant PTSD development continues at an even pace. Currently, antidepressant and cognitive-behavioral therapy have the greatest evidence base but still do not yield a remission of PTSD symptoms in many patients. Off-label and novel treatments continue to be considered for more refractory and disabling cases of PTSD. Ketamine is one such treatment that has been discussed and utilized more often for treatment-resistant major depressive disorder (MDD). Its mechanism is controversial regarding its potential to create anxiety, but the perceived benefit of a rapid reduction of symptoms makes it worthy for study in animal models of, and possibly human studies in, PTSD. The current literature and theoretical mechanism of action is discussed in this manuscript.
鉴于全球范围内的多次军事行动和平民创伤，创伤后应激障碍（PTSD）持续成为新闻头条，由此导致的PTSD病例仍在稳步增加。目前，抗抑郁药和认知行为疗法有最充分的证据支持，但在许多患者中仍无法使PTSD症状缓解。对于更难治和致残的PTSD病例，仍在考虑使用非标签和新型治疗方法。氯胺酮就是这样一种治疗方法，它已被更频繁地讨论和用于治疗难治性重度抑郁症（MDD）。其产生焦虑的可能性的机制存在争议，但其快速减轻症状的显著益处使其值得在PTSD动物模型中进行研究，甚至可能在人体研究中进行研究。本文将讨论当前的文献及理论作用机制。
